← Back to Search

Extended CTA for Ischemic Stroke Detection (DAYLIGHT Trial)

N/A

Recruiting

Led By Luciano Sposato, MD

Research Sponsored by Lawson Health Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

DAYLIGHT Trial Summary

This trial will help us better understand the role of LAA thrombi in ESUS and identify risk factors for stroke recurrence. #ESUS #CryptogenicStroke #TEE #CTA #LAAThrombi

Who is the study for?

The DAYLIGHT trial is for adults who come to the emergency department or stroke clinic with a suspected stroke or mini-stroke. They don't need a confirmed diagnosis to join. However, pregnant individuals, those with severe kidney disease, past or active cancers of the head, neck, or chest; allergies to iodine-based contrast agents; or without vein access for IV contrast are excluded.Check my eligibility

What is being tested?

This study tests if an extended CT angiography (eCTA) can better detect blood clots in the heart's left atrial appendage compared to standard CT angiography (sCTA). Both groups will receive usual care for stroke evaluation but one group will have additional imaging extending below the carina.See study design

What are the potential side effects?

Potential side effects mainly relate to CTA and may include reactions to contrast dye like rash or itching, kidney function impairment especially in those already at risk, and discomfort from lying still during scanning.

DAYLIGHT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Primary Efficacy Outcome: participants with a confirmed or "highly suspected" newly diagnosed cardioaortic thrombus

Secondary outcome measures

Secondary Efficacy Outcome 1: participants diagnosed with a cardio-aortic embolic source that has an available guideline-supported treatment including thrombi, vegetation, and tumors that are not primarily detected by TTE.

Secondary efficacy outcome 2: participants diagnosed with a cardio-aortic embolic source known to increase the risk of stroke.

Secondary efficacy outcome 3: participants diagnosed with a cardio-aortic embolic source resulting in the initiation of a new secondary prevention treatment other than antiplatelet therapy.

Other outcome measures

Primary Safety Outcome 1: door to sCTA time vs door to eCTA

Secondary Safety Outcome 1: Door-to-needle

Secondary Safety Outcome 2: Door-to-groin puncture

+4 more

DAYLIGHT Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: extended CTAExperimental Treatment1 Intervention

The standard CTA will be extended 6 cm below the carina

Group II: standard CTAActive Control1 Intervention

Standard CTA performed as standard of care for Stroke Workup

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor

659 Previous Clinical Trials

412,902 Total Patients Enrolled

Luciano Sposato, MDPrincipal InvestigatorLondon Health Sciences Center, Western University

2 Previous Clinical Trials

56 Total Patients Enrolled

Rodrigo Bagur, MDPrincipal InvestigatorLondon Health Sciences Center, Western University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an active enrollment process for this research project?

"According to clinicaltrials.gov, this medical research is actively seeking participants as of October 4th 2023. It was originally listed on July 17th 2023."

Answered by AI

How many individuals are participating in the experiment?

"Affirmative. The information housed on clinicaltrials.gov reveals that this research endeavour is presently actively recruiting participants, having first been advertised in July of 2023 and last updated 4th October the same year. As part of their data collection efforts, they are aiming to enroll 583 people at a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

ComputeD tomogrAphy angiographY for Left atrIal appendaGe tHrombus Detection in Acute Ischemic sTroke (DAYLIGHT) Trial

2023. "ComputeD tomogrAphy angiographY for Left atrIal appendaGe tHrombus Detection in Acute Ischemic sTroke (DAYLIGHT) Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05522244.

All > Anterior Ischemic Optic Neuropathy